PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33821842-0	2021	Pretreatment HLADQA1-HLADRB1 Testing for the Prevention of Azathioprine-Induced Pancreatitis in Inflammatory Bowel Disease: A Prospective Cohort Study.	Azathioprine	59-71	major histocompatibility complex, class II, DQ alpha 1	Homo sapiens	13-28	
33821842-2	2021	The haplotype HLADQA1-HLADRB1*07:01A>C is strongly associated with azathioprine-induced pancreatitis in IBD.	Azathioprine	67-79	major histocompatibility complex, class II, DQ alpha 1	Homo sapiens	14-21	
33821842-3	2021	We aimed to evaluate whether pretreatment HLADQA1-HLADRB1*07:01A>C screening will reduce the risk of azathioprine-induced pancreatitis.	Azathioprine	101-113	major histocompatibility complex, class II, DQ alpha 1	Homo sapiens	42-49	
33821842-7	2021	RESULTS: HLADQA1-HLADRB1*07:01A>C screening resulted in an 11-fold reduction in the incidence of azathioprine-induced pancreatitis (n = 1/328 or 0.30% vs n = 13/373 or 3.4%).	Azathioprine	97-109	major histocompatibility complex, class II, DQ alpha 1	Homo sapiens	9-16	
33821842-10	2021	DISCUSSION: HLADQA1-HLADRB1*07:01A>C screening reduced the risk of azathioprine-induced pancreatitis; however, using this strategy to guide the use of azathioprine therapy in IBD may eliminate a large proportion of patients from being eligible for treatment with azathioprine.	Azathioprine	67-79	major histocompatibility complex, class II, DQ alpha 1	Homo sapiens	12-19	
33821842-10	2021	DISCUSSION: HLADQA1-HLADRB1*07:01A>C screening reduced the risk of azathioprine-induced pancreatitis; however, using this strategy to guide the use of azathioprine therapy in IBD may eliminate a large proportion of patients from being eligible for treatment with azathioprine.	Azathioprine	151-163	major histocompatibility complex, class II, DQ alpha 1	Homo sapiens	12-19	
33821842-10	2021	DISCUSSION: HLADQA1-HLADRB1*07:01A>C screening reduced the risk of azathioprine-induced pancreatitis; however, using this strategy to guide the use of azathioprine therapy in IBD may eliminate a large proportion of patients from being eligible for treatment with azathioprine.	Azathioprine	151-163	major histocompatibility complex, class II, DQ alpha 1	Homo sapiens	12-19	
33821842-11	2021	In regions where there is access to other IBD therapies, and given the short-term and long-term toxicities associated with azathioprine, HLADQA1-HLADRB1*07:01A>C-screening may be a clinically relevant strategy for enhancing the safe use of azathioprine in IBD.	Azathioprine	123-135	major histocompatibility complex, class II, DQ alpha 1	Homo sapiens	137-144	
33821842-11	2021	In regions where there is access to other IBD therapies, and given the short-term and long-term toxicities associated with azathioprine, HLADQA1-HLADRB1*07:01A>C-screening may be a clinically relevant strategy for enhancing the safe use of azathioprine in IBD.	Azathioprine	240-252	major histocompatibility complex, class II, DQ alpha 1	Homo sapiens	137-144	
35120281-8	2022	We conclude that HLA-DQA1*02:01-HLA-DRB1*07:01 is a marker for increased risk of acute pancreatitis in individuals of Swedish genetic origin, treated with azathioprine for Crohn"s disease.	Azathioprine	155-167	major histocompatibility complex, class II, DQ alpha 1	Homo sapiens	17-25	
29270995-0	2018	HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease.	Azathioprine	55-67	major histocompatibility complex, class II, DQ alpha 1	Homo sapiens	0-17